SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab trades jubilantly on getting US FDA’s nod for Adenoscan Injection

25 Mar 2014 Evaluate

Strides Arcolab is currently trading at Rs. 382.10, up by 17.05 points or 4.67% from its previous closing of Rs. 365.05 on the BSE.

The scrip opened at Rs. 365.80 and has touched a high and low of Rs. 389.00 and Rs. 363.25 respectively. So far 267385 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1050.00 on 05-Dec-2013 and a 52 week low of Rs. 343.80 on 26-Feb-2014.

Last one week high and low of the scrip stood at Rs. 389.00 and Rs. 357.00 respectively. The current market cap of the company is Rs. 2173.55 crore.

The promoters holding in the company stood at 27.17% while Institutions and Non-Institutions held 52.29% and 20.54% respectively.

Strides Arcolab has received US Food and Drug Administration (US FDA) approval for Adenoscan Injection Generic. Astellas Pharma’s heart drug Adenoscan sales stood at $65 million per year. Teva pharma’s Adenoscan exclusivity has ended on March 23, 2014.

Adenoscan is used for diagnostic purposes as an adjunct to thallium-201 myocardial perfusion scintigraphy. Adenocard and generic adenosine products are labeled for use in paroxysmal supraventricular tachycardia.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×